Exelixis (EXEL) Announces Cabozantinib Phase 2 Met Primary Endpoint in RCC
Tweet Send to a Friend
Exelixis, Inc. (Nasdaq: EXEL) announced positive top-line results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
